Cargando…

Identifying metabolic features of colorectal cancer liability using Mendelian randomization

BACKGROUND: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. METHODS: To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bull, Caroline J., Hazelwood, Emma, Bell, Joshua A., Tan, Vanessa Y., Constantinescu, Andrei-Emil, Borges, Maria Carolina, Legge, Danny N., Burrows, Kimberly, Huyghe, Jeroen R., Brenner, Hermann, Castellví-Bel, Sergi, Chan, Andrew T, Kweon, Sun-Seog, Marchand, Loic Le, Li, Li, Cheng, Iona, Pai, Rish K., Figueiredo, Jane C., Murphy, Neil, Gunter, Marc J., Timpson, Nicholas J., Vincent, Emma E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029059/
https://www.ncbi.nlm.nih.gov/pubmed/36945480
http://dx.doi.org/10.1101/2023.03.10.23287084
_version_ 1785145836683919360
author Bull, Caroline J.
Hazelwood, Emma
Bell, Joshua A.
Tan, Vanessa Y.
Constantinescu, Andrei-Emil
Borges, Maria Carolina
Legge, Danny N.
Burrows, Kimberly
Huyghe, Jeroen R.
Brenner, Hermann
Castellví-Bel, Sergi
Chan, Andrew T
Kweon, Sun-Seog
Marchand, Loic Le
Li, Li
Cheng, Iona
Pai, Rish K.
Figueiredo, Jane C.
Murphy, Neil
Gunter, Marc J.
Timpson, Nicholas J.
Vincent, Emma E.
author_facet Bull, Caroline J.
Hazelwood, Emma
Bell, Joshua A.
Tan, Vanessa Y.
Constantinescu, Andrei-Emil
Borges, Maria Carolina
Legge, Danny N.
Burrows, Kimberly
Huyghe, Jeroen R.
Brenner, Hermann
Castellví-Bel, Sergi
Chan, Andrew T
Kweon, Sun-Seog
Marchand, Loic Le
Li, Li
Cheng, Iona
Pai, Rish K.
Figueiredo, Jane C.
Murphy, Neil
Gunter, Marc J.
Timpson, Nicholas J.
Vincent, Emma E.
author_sort Bull, Caroline J.
collection PubMed
description BACKGROUND: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. METHODS: To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years. RESULTS: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. CONCLUSIONS: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development. FUNDING: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/.
format Online
Article
Text
id pubmed-10029059
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-100290592023-11-14 Identifying metabolic features of colorectal cancer liability using Mendelian randomization Bull, Caroline J. Hazelwood, Emma Bell, Joshua A. Tan, Vanessa Y. Constantinescu, Andrei-Emil Borges, Maria Carolina Legge, Danny N. Burrows, Kimberly Huyghe, Jeroen R. Brenner, Hermann Castellví-Bel, Sergi Chan, Andrew T Kweon, Sun-Seog Marchand, Loic Le Li, Li Cheng, Iona Pai, Rish K. Figueiredo, Jane C. Murphy, Neil Gunter, Marc J. Timpson, Nicholas J. Vincent, Emma E. medRxiv Article BACKGROUND: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. METHODS: To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years. RESULTS: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. CONCLUSIONS: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development. FUNDING: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/. Cold Spring Harbor Laboratory 2023-11-09 /pmc/articles/PMC10029059/ /pubmed/36945480 http://dx.doi.org/10.1101/2023.03.10.23287084 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Bull, Caroline J.
Hazelwood, Emma
Bell, Joshua A.
Tan, Vanessa Y.
Constantinescu, Andrei-Emil
Borges, Maria Carolina
Legge, Danny N.
Burrows, Kimberly
Huyghe, Jeroen R.
Brenner, Hermann
Castellví-Bel, Sergi
Chan, Andrew T
Kweon, Sun-Seog
Marchand, Loic Le
Li, Li
Cheng, Iona
Pai, Rish K.
Figueiredo, Jane C.
Murphy, Neil
Gunter, Marc J.
Timpson, Nicholas J.
Vincent, Emma E.
Identifying metabolic features of colorectal cancer liability using Mendelian randomization
title Identifying metabolic features of colorectal cancer liability using Mendelian randomization
title_full Identifying metabolic features of colorectal cancer liability using Mendelian randomization
title_fullStr Identifying metabolic features of colorectal cancer liability using Mendelian randomization
title_full_unstemmed Identifying metabolic features of colorectal cancer liability using Mendelian randomization
title_short Identifying metabolic features of colorectal cancer liability using Mendelian randomization
title_sort identifying metabolic features of colorectal cancer liability using mendelian randomization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029059/
https://www.ncbi.nlm.nih.gov/pubmed/36945480
http://dx.doi.org/10.1101/2023.03.10.23287084
work_keys_str_mv AT bullcarolinej identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT hazelwoodemma identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT belljoshuaa identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT tanvanessay identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT constantinescuandreiemil identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT borgesmariacarolina identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT leggedannyn identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT burrowskimberly identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT huyghejeroenr identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT brennerhermann identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT castellvibelsergi identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT chanandrewt identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT kweonsunseog identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT marchandloicle identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT lili identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT chengiona identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT pairishk identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT figueiredojanec identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT murphyneil identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT guntermarcj identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT timpsonnicholasj identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization
AT vincentemmae identifyingmetabolicfeaturesofcolorectalcancerliabilityusingmendelianrandomization